Table 1.
Clinical characteristics of the HIV-1 infected subjects
| Group | Early | Late Control | Late Failure | Treatment naïve | ||
|---|---|---|---|---|---|---|
| No. of Subjects | 13 | 30 | 21 | 6 | ||
| Male | 3 | 14 | 10 | 2 | ||
| Female | 10 | 16 | 11 | 4 | ||
| Age mean (±SD) | 6.8 (±3.2) | 13.7 (±4.1) | 15.8 (±4.1) | 11.8 (±4.3) | ||
| CDC status at diagnosis | N | 1 | 3 | 3 | 1 | |
| A | 3 | 8 | 1 | 1 | ||
| B | 1 | 11 | 8 | 4 | ||
| C | 8 | 8 | 9 | 0 | ||
| HIV-1 viral load mean copies/ml (±SD) | <50 (±0) | <05 (±0) | 7,519 (±15017) | 22,133 (±19473) | ||
| Months of HIV-1 viral load control Mean (±SD) | 53.9 (±26.7) | 48.3 (±24.3) | 0 (±0) | 0 (±0) | ||
| CD4+ counts median (range) | 817 (353–2,964) | 665 (225–1,208) | 399 (265–998) | 368 (298–906) | ||
| CD4+ %median (range) | 35 (25–46) | 33 (16–48) | 22 (10–41) | 25 (19–33) | ||
| CD19+ %median (range) | 16 (9–30) | 15 (10–29) | 15 (4–45) | 10 (7–16) | ||
| HAART initiation age mean (±SD) | 6.8 months (±3.0) | 7.4 years (±4.9) | 6.7 years (±3.9) | none | ||
| Years from vaccination or boost mean (±SD) | Measles | 4.2 (±2.7) | 4.7 (±4.5) | 3.7 (±3.0) | 6.1 (±3.2) | |
| Tetanus | 5.3 (±2.4) | 7.4 (±3.8) | 9.7 (±5.2) | 5.0 (±2.0) | ||
| Pneumococcus | 3.8 (±3.5) | 3.8 (±1.6) | 3.9 (±1.0) | 3.0 (±1.7) |